Jean Michel Karsenti
Université Côte d'Azur(FR)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Pneumocystis jirovecii pneumonia detection and treatment, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients(2012)82 cited
- → Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study(2020)82 cited
- → Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines(2014)22 cited
- → BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia(2017)20 cited
- → Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA(2014)18 cited
- → Clonal selection in therapy‐related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment(2020)11 cited
- → Isolated lymphadenopathy inLeishmania infantuminfection: three case reports(2009)6 cited
- → Lymphomes non hodgkiniens B associés au virus de l'immunodéficience humaine et infection par le virus de l'hépatite C : étude cas-témoins rétrospective(2001)1 cited
- → 231 Azacitidine-resistant SKM1 MDS cells are defective for mitochondrial apoptosis and exhibit increased basal autophagy(2011)1 cited
- [Acquired von Willebrand's disease, cryoglobulinemia and pseudoanalbuminemia in monoclonal dysglobulinemia].(1990)